Joseph P. Horrigan, MD, is a pediatric neuropsychiatrist. He has specialized in the treatment of children with complex neurodevelopmental disorders for more than 30 years. In addition, he has 24 years of experience in the various roles associated with the pharmaceutical and biotech industries, both as a clinical investigator and as a sponsor.
Dr. Horrigan was a Senior Director in the Neurosciences Medicines Development Center at GlaxoSmithKline, where he also co-founded and led the company-wide Medicines for Children Advisory Network that collaborated with all therapeutic areas in the company. Dr. Horrigan also served as Assistant Vice President and Head of Medical Research for Autism Speaks, the largest science and advocacy organization in the U.S. devoted to autism spectrum disorders (ASD). He subsequently served as Vice President of Clinical Development and Medical Affairs for Neuren Pharmaceuticals Limited, leading that company’s pioneering clinical development efforts in neurodevelopmental disorders such as Rett syndrome and Fragile X syndrome, as well as in traumatic brain injury. Dr. Horrigan is currently the Chief Medical Officer for AMO Pharma Ltd., an emerging biopharmaceutical company that is focusing on orphan diseases, neuromuscular and neurodevelopmental disorders with significant unmet medical needs.
Dr. Horrigan received his Sc.B. degree from Brown University and his medical degree from the University of Rochester. Dr. Horrigan has been a longstanding scientific advisor to FRAXA, he is a newly-elected Board member of Rettsyndrome.org, and he is also a Consulting Associate Professor at the Duke University Center for Autism and Brain Development in Durham, North Carolina.